- Title
- Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta‐analysis
- Creator
- Kow, Chia Siang; Hasan, Syed Shahzad
- Relation
- Journal of Thrombosis and Thrombolysis Vol. 52, Issue 1, p. 124-129
- Publisher Link
- http://dx.doi.org/10.1007/s11239-021-02436-0
- Publisher
- Springer
- Resource Type
- journal article
- Date
- 2021
- Description
- Globally, there have been close to 130 million reported cases of coronavirus disease 2019 (COVID-19) as of 2nd April 2021, with 2.8 million deaths documented [1]. In order to reduce the risk of mortality associated with COVID-19, several drugs have been repurposed for its treatment. However, a drug with widespread availability around the globe is particularly desirable to be repurposed for the treatment of COVID-19, since it could be immediately trialed in large-scale studies, and immediate access could be guaranteed shall the drug is proven effective to reduce the risk of COVID-19 associated deaths. One of the first drugs to be introduced for routine usage in the medical field - aspirin (also known as acetylsalicylic acid), is still one of the most widely used medications, with an estimated 50–120 billion pills consumed each year [2]. In addition, it is one of the most researched drugs in the world, with an estimated 700–1000 clinical trials conducted annually.
- Subject
- COVID-19; mortality; drugs; aspirin; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1450236
- Identifier
- uon:43872
- Identifier
- ISSN:0929-5305
- Language
- eng
- Reviewed
- Hits: 216
- Visitors: 216
- Downloads: 0